CervoMed Advances Neflamapimod With New Tablet and FDA Dose Flexibility
BOSTON — September 28, 2026 CervoMed Inc. announced pharmacokinetic, regulatory and manufacturing advances for neflamapimod, including a new 50...
pharmacokinetics
Advertisement
Hemab Doses First Participant in HMB-003 Phase 1
CAMBRIDGE, Mass. and COPENHAGEN, Denmark — September 17, 2026 Hemab Therapeutics announced that the first healthy volunteer has been...
MIRA Advances Ketamir-2 Toward Phase 2a in CIPN
MIAMI, Fla. — September 17, 2026 MIRA Pharmaceuticals announced that its Phase 2a protocol for Ketamir-2 in chemotherapy-induced peripheral...
Avacta Achieves Clinical Proof of Mechanism for AVA6103
LONDON and PHILADELPHIA — September 16, 2026 Avacta Therapeutics announced clinical proof of mechanism for AVA6103, its next-generation controlled-release...
Fennec Pharmaceuticals Presents Two-Year Pedmark Data in Japan
RESEARCH TRIANGLE PARK, N.C. — September 17, 2026 Fennec Pharmaceuticals announced the oral presentation of detailed results from the...
Advertisements
Aquestive Resubmits Anaphylm NDA to FDA
WARREN, N.J. — September 17, 2026 Aquestive Therapeutics announced the resubmission of its New Drug Application (NDA) to the...
Santa Ana Bio Advances SAB01 Into Phase 1
ALAMEDA, Calif. — September 14, 2026 Santa Ana Bio announced that the first cohort has been dosed in the...
Nutromics Receives FDA Breakthrough Device Designation
Melbourne, Australia, September 10, 2026 Nutromics has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough...
MetaVia Reports Preclinical Data on DA-1726 Waist Reduction
Cambridge, Massachusetts, September 9, 2026 MetaVia Inc., a clinical-stage biotechnology company focused on cardiometabolic diseases, has reported new preclinical...
ViiV Healthcare’s Tivicay PD Wins FDA Approval for Kids
LONDON, Aug 26, 2026 The U.S. Food and Drug Administration (FDA) has approved Tivicay PD (dolutegravir) from ViiV Healthcare...
Advertisement
